When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
In the GUIDED study, pharmacogenomic testing significantly improved response and remission rates for difficult-to-treat depression patients over the standard of care.
In this video, recorded at the World Stem Cell Summit 2019, Julie Allickson, PhD, discusses past and current research conducted at the Wake Forest University School of Medicine’s…
New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
The proportion of risk for alcohol use disorder (AUD) that can be attributed to genetic factors is as high as 60%. This data invokes heritability comparisons to both…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
The Centers for Disease Control and Prevention (CDC) has produced a new video for healthcare providers who treat or dispense medications to women of reproductive age. This short…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared…
Abbott has developed two types of implantable neurostimulation devices that employ two advanced spinal column stimulation (SCS) techniques, respectively, dorsal root ganglion (DRG) stimulation and Abbott’s proprietary BURSTDR™…
